J&J is seeking to undo a lower court ruling from October that invalidated a patent relating to Zytiga, opening the door for generic competition.
U.S. appeals court declines J&J bid to stop generic Zytiga sales
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain